Disease risk and life expectancy, and not chronological age, should determine prostate-cancer (PCa) treatment, suggests a recent analysis detailed in the Journal of Clinical Oncology (2011;29:235-241).

Data from 13,805 PCa patients in the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) data base revealed that 26% of men aged 75 years and older presented with high-risk disease.

These patients were more likely than younger patients to undergo androgen deprivation monotherapy, even though the high-risk older men who received more aggressive local treatment had a 46% reduction in mortality compared with those treated conservatively.

Continue Reading